Decoding the cellular mechanisms of COVID-19 severe disease susceptibility in patients with chronic respiratory disease
解读慢性呼吸道疾病患者COVID-19重症易感性的细胞机制
基本信息
- 批准号:10185342
- 负责人:
- 金额:$ 83.95万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-09-20 至 2023-08-31
- 项目状态:已结题
- 来源:
- 关键词:2019-nCoVACE2Angiotensin ReceptorAntibodiesAntibody DiversityAtlasesAutomobile DrivingAutopsyBiological AssayBiologyCOVID-19COVID-19 pandemicCOVID-19 patientCOVID-19 susceptibilityCOVID-19 treatmentCell CommunicationCellsCellular AssayChromatinChronicChronic Obstructive Airway DiseaseCollaborationsCollectionComplementary DNAComputer AnalysisComputer ModelsCoronavirusCoronavirus InfectionsDataDiseaseDisease susceptibilityDistalEpigenetic ProcessEpithelial CellsGene ExpressionGenetic TranscriptionGenetic VariationGenomicsGoalsHistologicHumanImmuneImmune responseImmune systemIncidenceIndividualInfectionLigandsLinkLocationLungLung diseasesMeasurementMediatingMediator of activation proteinMolecularNatureNoseNucleic Acid Regulatory SequencesNucleotidesOrganOther GeneticsPathologyPathway interactionsPatientsPatternPeptide HydrolasesPositioning AttributeProtein IsoformsPublic HealthRNARegulationRegulator GenesReportingResearchResolutionSARS coronavirusSARS-CoV-2 genomeSARS-CoV-2 infectionSamplingSerine ProteaseSeveritiesStructure of parenchyma of lungSurfaceSurveysT-Cell ReceptorTMPRSS2 geneTechnologyTissuesTranscriptTransposaseTreatment ProtocolsUnited StatesViralVirusVirus Diseasescell typeco-infectioncohortcomorbiditycytokinedata integrationdisease phenotypegenetic profilinghigh riskhuman coronavirusimprovedinsightnew therapeutic targetnovel coronavirusnovel therapeuticsprogramsreceptorrecruitrespiratoryresponsesevere COVID-19single cell analysissingle-cell RNA sequencingtranscription factortranscriptomicstreatment strategytumor-immune system interactionsvirus host interactionwhole genome
项目摘要
PROJECT SUMMARY
The new coronavirus (SARS-CoV-2) and associated disease (COVID-19) is a global threat to worldwide
economies and public health due to its highly contagious nature and rapid spread. To develop optimal
strategies for treatment of COVID-19, it is critical to understand the cell types and molecular mechanisms that
mediate coronavirus infection, tissue propagation, and host immune response. As recently reported, both
SARS-CoV and SARS-CoV-2 use the host ACE2 receptor protein and protease TMPRSS2 to gain cellular
entry. High-throughput single-cell RNA-sequencing (scRNA-seq) and Assay for Transposase-Accessible
Chromatin (scATAC-seq) now allow us to interrogate cell types and cell states at unprecedented resolution,
which has led to groundbreaking discoveries in lung tissue biology, including our lab’s and the Human Cell
Atlas recent survey of nasal and lung epithelial cell types that co-express ACE2 and TMPRSS2 consistent with
disease phenotype. It has been reported that individuals suffering from chronic respiratory diseases are more
susceptible to COVID-19 severe disease. We propose to leverage our expertise in lung biology, single-cell
analysis, and unique access to lung tissue at Mount Sinai from COVID-19 patients with chronic respiratory
disease comorbidities to define the cell types and regulatory mechanisms that mediate COVID-19 disease
susceptibility due to SARS-CoV-2 infection, propagation and interplay with the host immune response.
Towards this goal, we will perform scRNA-seq, scATAC-seq, and spatial transcriptomic sequencing of multiple
infected and non-infected lung regions in 25-30 patients with COVID-19 and chronic obstructive pulmonary
disease comorbidity following autopsy. The single-cell resolution data will allow us to characterize the
repertoire of SARS-CoV-2 infected cell and surrounding stromal and immune microenvironment and how they
contribute to developing COVID-19 severe disease. Analysis of scATAC-seq data from matched lung regions
will identify the key transcription factors and regulatory mechanisms driving the expression programs related to
viral infection, host immune response, and severe disease susceptibility. Finally, integration of ligand-receptor
pair expression and spatial transcriptomics information will elucidate at greater resolution and scale how cell-
cell interactions and tissue pathology are altered after coronavirus infection. Single-cell characterization of the
cell types, immune response, and regulatory mechanisms of infection will improve our understanding of virus-
host interactions and COVID-19 severe disease susceptibility in patients with chronic respiratory disease. This
will, in turn, provide mechanistic insight towards discovering new therapeutic targets that specifically benefit
COVID-19 patients with pre-existing respiratory conditions.
项目总结
新型冠状病毒(SARS-CoV-2)及相关疾病(新冠肺炎)是世界性的全球性威胁
由于它的高度传染性和迅速传播,它对经济和公共卫生造成了巨大的影响。开发最优产品
对于新冠肺炎的治疗策略,了解其细胞类型和分子机制是至关重要的
调节冠状病毒感染、组织繁殖和宿主免疫反应。正如最近报道的那样,两者
SARS-CoV和SARS-CoV-2利用宿主ACE2受体蛋白和蛋白酶TMPRSS2获得细胞
进入。高通量单细胞RNA测序(scRNA-seq)及转座酶可及性检测
染色质(scatac-seq)现在允许我们以前所未有的分辨率询问细胞类型和细胞状态,
这导致了肺组织生物学的突破性发现,包括我们的实验室和人类细胞
共同表达ACE2和TMPRSS2的鼻腔和肺上皮细胞类型的Atlas最新调查与
疾病表型。有报道称,患有慢性呼吸道疾病的个人更多
易患新冠肺炎重症疾病。我们建议利用我们在肺部生物学方面的专业知识,单细胞
新冠肺炎慢性呼吸道疾病患者在西奈山的肺组织分析和独特获取
疾病并存以确定介导新冠肺炎病的细胞类型和调控机制
由于SARS-CoV-2感染的易感性、繁殖和与宿主免疫反应的相互作用。
为了实现这一目标,我们将进行scRNA-seq、scatac-seq和多个
25~30例新冠肺炎合并慢性阻塞性肺疾病患者感染和非感染肺区分析
尸检后的疾病共病。单元格分辨率数据将使我们能够表征
SARS-CoV-2感染细胞及其周围基质和免疫微环境的研究进展
助力发展新冠肺炎大病。来自匹配肺区的SCATAC-SEQ数据分析
将确定驱动相关表达程序的关键转录因子和调控机制
病毒感染、宿主免疫反应和严重疾病易感性。最后,配体-受体的整合
配对表达和空间转录信息将以更高的分辨率和规模阐明细胞如何-
冠状病毒感染后细胞相互作用和组织病理改变。细胞的单细胞特性
感染的细胞类型、免疫反应和调节机制将提高我们对病毒的理解--
宿主相互作用与慢性呼吸道疾病患者新冠肺炎严重疾病易感性的关系。这
反过来,将提供对发现新的治疗靶点的机械洞察力,这些靶点特别有益
新冠肺炎患者有既往呼吸道疾病。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Alexander Minchev Tsankov其他文献
Alexander Minchev Tsankov的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Alexander Minchev Tsankov', 18)}}的其他基金
Comparative, single-cell analysis of COVID-19 and other respiratory diseases
COVID-19 和其他呼吸道疾病的比较单细胞分析
- 批准号:
10361031 - 财政年份:2022
- 资助金额:
$ 83.95万 - 项目类别:
Comparative, single-cell analysis of COVID-19 and other respiratory diseases
COVID-19 和其他呼吸道疾病的比较单细胞分析
- 批准号:
10549811 - 财政年份:2022
- 资助金额:
$ 83.95万 - 项目类别:
Single-cell analysis of the lung immune microenvironment and cell-cell interactions across healthy and diseased patients
对健康和患病患者的肺部免疫微环境和细胞间相互作用的单细胞分析
- 批准号:
10293348 - 财政年份:2021
- 资助金额:
$ 83.95万 - 项目类别:
Single-cell analysis of the lung immune microenvironment and cell-cell interactions across healthy and diseased patients
对健康和患病患者的肺部免疫微环境和细胞间相互作用的单细胞分析
- 批准号:
10472702 - 财政年份:2021
- 资助金额:
$ 83.95万 - 项目类别:
Uncovering the transcription factor networks in early human cell specification
揭示早期人类细胞规范中的转录因子网络
- 批准号:
8526759 - 财政年份:2013
- 资助金额:
$ 83.95万 - 项目类别:
Uncovering the transcription factor networks in early human cell specification
揭示早期人类细胞规范中的转录因子网络
- 批准号:
8625642 - 财政年份:2013
- 资助金额:
$ 83.95万 - 项目类别:
相似国自然基金
新型蝙蝠MERS簇冠状病毒HKU5的ACE2细胞受体识别及其分子机制研究
- 批准号:
- 批准年份:2024
- 资助金额:0.0 万元
- 项目类别:省市级项目
铁皮石斛通过肠道 ACE2 修复 Trp/GPR142 介
导“肠-胰岛 ”轴血糖调控功能的降糖机制研
究
- 批准号:Y24H280055
- 批准年份:2024
- 资助金额:0.0 万元
- 项目类别:省市级项目
CAFs来源的外泌体负性调控ACE2促进肾透明细胞癌癌栓新辅助靶向耐药的机制研究
- 批准号:82373169
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
人类ACE2变构抑制剂的成药性及其抗广谱冠状病毒感染的机制研究
- 批准号:82330111
- 批准年份:2023
- 资助金额:220 万元
- 项目类别:重点项目
新型蝙蝠MERS簇冠状病毒HKU5的ACE2受体识别及细胞入侵机制研究
- 批准号:32300137
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
基于AT2/ACE2/Ang(1-7)/MAS轴调控心脏-血管-血液系统性重构演变规律研究心衰气虚血瘀证及其益气通脉活血化瘀治法生物学基础
- 批准号:82305216
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
基于外泌体miRNAs介导细胞通讯的大豆ACE2激活肽调控血管稳态机制研究
- 批准号:32302080
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
感毒清经ACE2/Ang(1-7)/MasR信号通路抑制PM2.5诱导慢性气道炎症的机制:聚焦肺泡巨噬细胞极化与“胞葬”的表型串扰
- 批准号:82305171
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
刺参自溶引发机制中ACE2调控靶点的调控网络研究
- 批准号:32372399
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
Spike变异对新冠病毒抗原性及ACE2种属嗜性的影响研究
- 批准号:82272305
- 批准年份:2022
- 资助金额:52 万元
- 项目类别:面上项目
相似海外基金
新型コロナウイルス感染阻害能を有する抗ACE2抗体の阻害機構に関する構造基盤解明
阐明具有抑制新型冠状病毒感染能力的抗ACE2抗体抑制机制的结构基础
- 批准号:
24K09338 - 财政年份:2024
- 资助金额:
$ 83.95万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
ACE2のユビキチン化を介したコロナウイルス感染機構の解明と創薬への挑戦
通过ACE2泛素化阐明冠状病毒感染机制和药物发现的挑战
- 批准号:
22KJ2499 - 财政年份:2023
- 资助金额:
$ 83.95万 - 项目类别:
Grant-in-Aid for JSPS Fellows
ACE2阻害薬およびERK経路阻害薬による慢性腎炎進展抑制効果の検証
ACE2抑制剂和ERK通路抑制剂抑制慢性肾炎进展的效果验证
- 批准号:
23K14982 - 财政年份:2023
- 资助金额:
$ 83.95万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Large-scale compatibility assessments between ACE2 proteins and diverse sarbecovirus spikes
ACE2 蛋白和多种 sarbecovirus 尖峰之间的大规模兼容性评估
- 批准号:
10722852 - 财政年份:2023
- 资助金额:
$ 83.95万 - 项目类别:
一次線毛とコロナウイルス感染におけるACE2の役割の解明
阐明 ACE2 在原发菌毛和冠状病毒感染中的作用
- 批准号:
22KF0004 - 财政年份:2023
- 资助金额:
$ 83.95万 - 项目类别:
Grant-in-Aid for JSPS Fellows
The regulatory roles of ACE2 and its interaction with Nrf2 in arsenic-induced endothelial dysfunction in experimental and epidemiological studies
实验和流行病学研究中 ACE2 的调节作用及其与 Nrf2 的相互作用在砷诱导的内皮功能障碍中的作用
- 批准号:
23K16310 - 财政年份:2023
- 资助金额:
$ 83.95万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Role of ACE2 in the mechanism of intestinal regeneration
ACE2在肠道再生机制中的作用
- 批准号:
23K15078 - 财政年份:2023
- 资助金额:
$ 83.95万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Research and development of a novel pediatric anti-obesity medicine via ACE2 activation in DIZE
通过 DIZE 中 ACE2 激活研发新型儿科抗肥胖药物
- 批准号:
23K15417 - 财政年份:2023
- 资助金额:
$ 83.95万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Lung delivery of novel ACE2 variants for COVID-19
针对 COVID-19 的新型 ACE2 变体的肺部输送
- 批准号:
10483042 - 财政年份:2022
- 资助金额:
$ 83.95万 - 项目类别:
ACE2 on gut barrier dysfunction and BRB disruption
ACE2 对肠道屏障功能障碍和 BRB 破坏的影响
- 批准号:
10535485 - 财政年份:2022
- 资助金额:
$ 83.95万 - 项目类别: